New Atlas January 23, 2024
Paul McClure

The FDA has approved a wearable belt that delivers targeted vibrations to the spine and hips as the first non-drug prescription medical device to treat low bone density, the precursor to osteoporosis. Shown to be effective in clinical trials, the novel device offers postmenopausal women an alternative treatment to vitamin and mineral supplements.

Postmenopausal women are at high risk of fractures due to loss of the hormone estrogen. Because estrogen helps maintain bone density, this loss can lead to osteopenia or low bone density. The precursor to osteoporosis, osteopenia affects 40.4% of people globally.

Developed by Bone Health Technologies (BHT), Osteoboost is a novel wearable belt device that delivers vibrations to the lumbar spine and hips to...

Today's Sponsors

Venturous
Got healthcare questions? Just ask Transcarent

Today's Sponsor

Venturous

 
Topics: Digital Health, FDA, Govt Agencies, Patient / Consumer, Provider, Technology, Wearables
Key Benefits of CGM Technology
'We can nip a pandemic in the bud with smartwatches'
Flattening the curve: How smartwatches could help stop a pandemic before it even begins
Unlocking the power of sensor data in type 2 diabetes care
Google’s Pixel Watch 3 Loss of Pulse Detection Feature Receives FDA Clearance

Share This Article